These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 16838228)
1. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Louie TJ; Peppe J; Watt CK; Johnson D; Mohammed R; Dow G; Weiss K; Simon S; John JF; Garber G; Chasan-Taber S; Davidson DM; Clin Infect Dis; 2006 Aug; 43(4):411-20. PubMed ID: 16838228 [TBL] [Abstract][Full Text] [Related]
2. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM; Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326 [TBL] [Abstract][Full Text] [Related]
3. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Weiss K Int J Antimicrob Agents; 2009 Jan; 33(1):4-7. PubMed ID: 18804351 [TBL] [Abstract][Full Text] [Related]
4. Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea. Scheinfeld N; Biggers K Curr Opin Investig Drugs; 2008 Aug; 9(8):913-24. PubMed ID: 18666039 [TBL] [Abstract][Full Text] [Related]
5. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Cornely OA; Crook DW; Esposito R; Poirier A; Somero MS; Weiss K; Sears P; Gorbach S; Lancet Infect Dis; 2012 Apr; 12(4):281-9. PubMed ID: 22321770 [TBL] [Abstract][Full Text] [Related]
6. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Nelson R Cochrane Database Syst Rev; 2007 Jul; (3):CD004610. PubMed ID: 17636768 [TBL] [Abstract][Full Text] [Related]
7. Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile. Hinkson PL; Dinardo C; DeCiero D; Klinger JD; Barker RH Antimicrob Agents Chemother; 2008 Jun; 52(6):2190-5. PubMed ID: 18391047 [TBL] [Abstract][Full Text] [Related]
9. A new formulation of tolevamer, a novel nonantibiotic polymer, is safe and well-tolerated in healthy volunteers: a randomized phase I trial. Peppe J; Porzio A; Davidson DM Br J Clin Pharmacol; 2008 Jul; 66(1):102-9. PubMed ID: 18341677 [TBL] [Abstract][Full Text] [Related]
10. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. Akerlund T; Svenungsson B; Lagergren A; Burman LG J Clin Microbiol; 2006 Feb; 44(2):353-8. PubMed ID: 16455883 [TBL] [Abstract][Full Text] [Related]
11. Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection. Louie T; Nord CE; Talbot GH; Wilcox M; Gerding DN; Buitrago M; Kracker H; Charef P; Cornely OA Antimicrob Agents Chemother; 2015 Oct; 59(10):6266-73. PubMed ID: 26248357 [TBL] [Abstract][Full Text] [Related]
12. Fidaxomicin versus vancomycin for Clostridium difficile infection. Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK; N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. Kokkotou E; Moss AC; Michos A; Espinoza D; Cloud JW; Mustafa N; O'Brien M; Pothoulakis C; Kelly CP Antimicrob Agents Chemother; 2008 Mar; 52(3):1121-6. PubMed ID: 18195066 [TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964 [TBL] [Abstract][Full Text] [Related]
15. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Zar FA; Bakkanagari SR; Moorthi KM; Davis MB Clin Infect Dis; 2007 Aug; 45(3):302-7. PubMed ID: 17599306 [TBL] [Abstract][Full Text] [Related]
16. Clostridium difficile infection. Kelly CP; LaMont JT Annu Rev Med; 1998; 49():375-90. PubMed ID: 9509270 [TBL] [Abstract][Full Text] [Related]
17. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Lewis S; Burmeister S; Brazier J Clin Gastroenterol Hepatol; 2005 May; 3(5):442-8. PubMed ID: 15880313 [TBL] [Abstract][Full Text] [Related]
18. Toxin binding of tolevamer, a polyanionic drug that protects against antibiotic-associated diarrhea. Braunlin W; Xu Q; Hook P; Fitzpatrick R; Klinger JD; Burrier R; Kurtz CB Biophys J; 2004 Jul; 87(1):534-9. PubMed ID: 15240486 [TBL] [Abstract][Full Text] [Related]
19. Treatment with monoclonal antibodies against Clostridium difficile toxins. Lowy I; Molrine DC; Leav BA; Blair BM; Baxter R; Gerding DN; Nichol G; Thomas WD; Leney M; Sloan S; Hay CA; Ambrosino DM N Engl J Med; 2010 Jan; 362(3):197-205. PubMed ID: 20089970 [TBL] [Abstract][Full Text] [Related]
20. Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. Cornely OA; Miller MA; Fantin B; Mullane K; Kean Y; Gorbach S J Clin Oncol; 2013 Jul; 31(19):2493-9. PubMed ID: 23715579 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]